Nueclear Web Banner
Users Online: 460
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 7  |  Issue : 2  |  Page : 142-145

Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer


1 Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India
2 Department of Medical Oncology, Mahaveer Cancer Sansthan, Patna, Bihar, India
3 Department of Medical Oncology, Hope Clinic, New Delhi, India
4 Department of Medical Oncology, KMIO, Bengaluru, Karnataka, India
5 Department of Medical Oncology, Max Hospital, New Delhi, India
6 Department of Medical Oncology, Jolly Grant Himalayan Institute, Dehradoon, Uttarakhand, India
7 Department of Medical Oncology, Bombay Hospital, Mumbai, Maharashtra, India
8 Department of Medical Oncology, Action Balajee Cancer Hospital, New Delhi, India
9 Department of Surgical Oncology, Sir Ganga Ram Hospital, New Delhi, India
10 Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
11 Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India

Correspondence Address:
Dr. Amish Vora
Department of Medical Oncology, Hope Clinic, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sajc.sajc_122_18

Rights and Permissions

Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). Expert oncologist discussed on the duration of adjuvant hormonal therapy for improvement of OS and quality of life of breast cancer patients by providing reduction in recurrence and mortality. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed187    
    Printed1    
    Emailed0    
    PDF Downloaded62    
    Comments [Add]    

Recommend this journal